Market Publishers

+357 96 030922
info@marketpublishers.com

Global HIV Infection Drug Pipeline Analysis

https://marketpublishers.com/r/G7AC6C24760EN.html
Date: October 2013
Pages: 300
Price: US$ 1,500.00 (Single User License)
ID: G7AC6C24760EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have been successful in improving the quality of life for HIV patients and prevented the virus from developing into AIDS. The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.6 in 2012, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years.

“Global HIV Infection Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process.
Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Drug Pipeline Analysis” research report:

Drug Profile Overview

Alternate Names for Drug

Active Indication

+357 96 030922
info@marketpublishers.com

- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes

HIV Infection Drug Development by Clinical Phase:

- Research: 31
- Preclinical: 140
- Phase-I: 53
- Phase-I/II: 18
- Phase-II: 39
- Phase-III: 7
- Preregistration: 2
- Registered: 2

Marketed: 34

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

9. HIV INFECTION DRUG CLINICAL DEVELOPMENT PHASE: REGISTERED

9.1 Overview
9.2 HIV Infection Drug Profiles in Clinical Phase

10. MARKETED DRUGS

10.1 Overview
10.2 Marketed Drug Profile

EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:

Alternate Names

Originator & Owner

Collaborator

Technology Provider

Licensee

Highest Development Phase

Indications

Class

Mechanism of Action

ATC Code

Designated Brand Name & Orphan Designation

+357 96 030922
info@marketpublishers.com

About

The discovery of HIV virus, which causes AIDS, dates back to 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have been successful in improving the quality of life for HIV patients and prevented the virus from developing into AIDS.

The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.6 in 2012, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years.

However, a major trend observed in this market has been that although the HIV infection rates are falling, the number of new patients being affected by the virus is increasing. With all the conscious efforts undertaken by all the related organizations and stakeholders, it is expected that by 2015, significant investments would be recorded in this field with the WHO setting an aim to treat close to 15 million HIV patients.

The market for HIV/AIDS therapeutics was valued at approximately USD 13.5 billion in 2011. With the various factors driving growth, this market is expected to reach close to USD 21.8 billion by 2018 by growing at a CAGR of 7%. The major markets include the United States, the United Kingdom, Germany, France, Italy, Spain and Japan. While the USA and European market continue to dominate the global pie, with a majority of the in come earned from these two regions, it is a fact that many dominant companies would start losing their market protection in 2017. Additionally, as a majority of the HIV-infected people is in developing countries, the drug makers are increasingly under pressure to reduce their costs significantly in regions like sub - Saharan Africa and to open up their products to generic competition. It has been estimated that approximately 46% of the global HIV market is occupied by generic versions of HIV drugs including zidovudine, didanosine, stavudine and lamivudine in 2010. However, with the emergence of more effective and economical therapies coming on line which would be more accessible to a greater number of people, the demand for novel therapies is still high.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global HIV Infection Drug Pipeline Analysis

Product link: https://marketpublishers.com/r/G7AC6C24760EN.html

Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G7AC6C24760EN.html